| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| PROEHL GERALD T | PRESIDENT, CHAIRMAN, CEO, Director, 10%+ Owner | 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO | /s/ Gerald T. Proehl, Attorney-in-Fact | 29 Dec 2025 | 0001279191 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DRMA | Common Stock | Award | +490,196 | +830841% | 490,255 | 23 Dec 2025 | By Proehl Family Trust | F1, F2, F3, F6 | ||
| transaction | DRMA | Common Stock | Award | +122,549 | +875350% | 122,563 | 23 Dec 2025 | By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 | F1, F2, F3, F6 | ||
| holding | DRMA | Common Stock | 24 | 23 Dec 2025 | Direct | F3 | |||||
| holding | DRMA | Common Stock | 7 | 23 Dec 2025 | By Allison Taylor Proehl 2020 Irrevocable Trust | F3, F6 | |||||
| holding | DRMA | Common Stock | 3 | 23 Dec 2025 | By Meghan Proehl Wilder 2020 Irrevocable Trust | F3, F6 | |||||
| holding | DRMA | Common Stock | 79,795 | 23 Dec 2025 | By Proehl Investment Ventures LLC | F3, F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DRMA | Series C Warrant (Right to Buy) | Award | +490,196 | +163399% | 490,496 | 23 Dec 2025 | Common Stock | 490,196 | $2.04 | By Proehl Family Trust | F1, F2, F4, F6 | ||
| transaction | DRMA | Series D Warrant (Right to Buy) | Award | +490,196 | +163399% | 490,496 | 23 Dec 2025 | Common Stock | 490,496 | $2.04 | By Proehl Family Trust | F1, F2, F5, F6 | ||
| transaction | DRMA | Series C Warrant (Right to Buy) | Award | +122,549 | 122,549 | 23 Dec 2025 | Common Stock | 122,549 | $2.04 | By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 | F1, F2, F4, F6 | |||
| transaction | DRMA | Series D Warrant (Right to Buy) | Award | +122,549 | 122,549 | 23 Dec 2025 | Common Stock | 122,549 | $2.04 | By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 | F1, F2, F5, F6 | |||
| transaction | DRMA | Warrant (Right to Buy) | Disposed to Issuer | +78,740 | 0 | 23 Dec 2025 | Common Stock | 78,740 | $12.70 | Direct | F3, F7 | |||
| transaction | DRMA | Warrant (Right to Buy) | Award | +78,740 | 78,740 | 23 Dec 2025 | Common Stock | 78,740 | $2.04 | Direct | F3, F7 |
| Id | Content |
|---|---|
| F1 | The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04. |
| F2 | The purchase price per share of common stock and accompanying warrants was $2.04. |
| F3 | Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. |
| F4 | This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. |
| F5 | This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. |
| F6 | Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| F7 | In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act. |